Publications
Current state of cardiac amyloidosis.
Sharma N, Howlett J.
Curr Opin Cardiol. 2013 Jan 14. http://www.ncbi.nlm.nih.gov/pubmed/23324855
Changes in Heart Failure Outcomes after a Province-Wide Change in Health Service Provision: A Natural Experiment in Alberta, Canada.
McAlister FA, Bakal JA, Kaul P, Quan H, Blackadar R, Johnstone D, Ezekowitz JA.
Circ Heart Fail. 2012 Dec 10. http://www.ncbi.nlm.nih.gov/pubmed/23230308
Random error in cardiovascular meta-analyses: How common are false positive and false negative results?
Albalawi Z, McAlister FA, Thorlund K, Wong M, Wetterslev J.
Int J Cardiol. 2012 Dec 3. http://www.ncbi.nlm.nih.gov/pubmed/23218569
Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization.
Au AG, McAlister FA, Bakal JA, Ezekowitz J, Kaul P, van Walraven C.
Am Heart J. 2012 Sep;164(3):365–72. http://www.ncbi.nlm.nih.gov/pubmed/22980303
Heart failure disease management programmes: a new paradigm for research.
Clark AM, Thompson DR.
Heart. 2012 Oct;98(20):1476–7. http://www.ncbi.nlm.nih.gov/pubmed/22791659
Resting and exercise cerebral blood flow in long-term heart transplant recipients.
Smirl JD, Haykowsky MJ, Nelson MD, Altamirano-Diaz LA, Ainslie PN.
J Heart Lung Transplant. 2012 Aug;31(8):906–8. http://www.ncbi.nlm.nih.gov/pubmed/22658714
Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations.
Linde C, Ellenbogen K, McAlister FA.
Heart Rhythm. 2012 Aug;9(8 Suppl):S3-S13. http://www.ncbi.nlm.nih.gov/pubmed/22521934
Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats.
Dolinsky VW, Jones KE, Sidhu RS, Haykowsky M, Czubryt MP, Gordon T, Dyck JR.
J Physiol. 2012 Jun 1;590(Pt 11):2783–99. http://www.ncbi.nlm.nih.gov/pubmed/22473781
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH.
Lancet. 2012 Nov 17;380(9855):1749–58. http://www.ncbi.nlm.nih.gov/pubmed/23036896
Heart failure incurs $3 billion in hospital costs annually.
One-year mortality rates for heart failure remain high (25-40%).
The burden of heart failure in Canada is expected to increase by 250% by 2025.
40-50% of heart failure patients are believed to have diastolic heart failure.
500,000 Canadians have been diagnosed with heart failure.
25-50% of heart failure patients are re-hospitalized within one year.
Total number of days spent in the hospital for heart failure is the second highest of any medical condition.
Heart failure affects a person’s quality of life more then any other chronic medical condition.
30% of heart failure patients, and more than 50% of heart failure patients over the age of 65, have been diagnosed specifically with diastolic heart failure.
Heart disease is most often diagnosed in older adults.
22% of hospitalizations in Alberta for heart failure occur in rural hospitals.
In Alberta, heart failure is common in rural settings.
In Alberta, heart failure causes 50% of all hospitalizations in adults age 65 and older.
80,000 Albertans have been diagnosed with heart failure.
Diastolic heart failure occurs when the heart fails to relax properly between heartbeats.
Systolic heart failure occurs when the heart does not contract properly.
Heart failure is a progressive condition where the heart weakens and cannot pump blood efficiently for the needs of the body.
Heart failure is at epidemic levels in most developed countries.
